Health Management International: Expect continued momentum in 2H18 February 14, 2018 956

PSR Recommendation: BUY Status: Maintained
Target Price: SGD0.83
  • Both 1H18 Revenue and PATMI met 49% of our full year FY2018 estimations
  • Margins expansion on patient volume and bill size growth, as well as realizing gain from its cost-saving measures
  • Declared interim dividend of RM1.0 Cents per share; Adopting dividend policy of paying out ≥20% of Core PATMI
  • Maintain ‘BUY’ with unchanged DCF-derived TP of S$0.83

1

The Positives

  • Expecting a strong FY18e. 1H18 Revenue/NPAT grew 7.7%/9.6% YoY. 2H is typically seasonally stronger. We expect revenue intensity and patient load growth to extend their upward trajectory. Meanwhile, its partnership with Gakken Cocofump to introduce elderly care training into Singapore and the region could add a new revenue stream to its Education business.
  • Foreign patient load growth (+15.5% YoY) continued to outpace local patient’s (2.8% YoY). Malaysia private healthcare services remain price competitive as compared to its neighbouring countries despite strengthening MYR. Recall that medical fees in Malaysia is moderated by the Medical Fee Schedule.
  • Intentional shift towards more outpatient services. The Group is moving towards handling more Day Surgery cases, in line with the growing demand. A faster growth in outpatient load (higher throughput), lower bed occupancy ratio (length of stay decreased), and a strong9% YoY growth from average outpatient bill size (higher revenue intensity), reflect increased efficiency and more Day Surgery cases. Its Day Surgery Centre in Mahkota Medical Centre (with two Day Surgery Units) is gaining traction.
  • Declared an interim dividend of RM1.0 Cents per share and adopting a dividend policy to payout not less 20% of the Group’s core earnings. We view the adoption of dividend policy positively and it should be supported by its strong operating cash flows. The payout ratio guided by the policy is the same as our initial forecast.

The Negatives

  • Finance costs increased by 6.7x due to the drawdown of S$53.0mn of the term loan facility for the purposes of the acquisition of non-controlling interests in Mahkota Medical Centre and Regency Specialist Hospital. Nonetheless, the pressure from finance costs should taper off as the Group has pared down 57% of its acquisition debt, bringing Net debt/T12M Ebitda and gearing ratio down to 0.3x and 0.2x from 1.7x and 0.5x in end-FY17, respectively.

Outlook

Outlook remains positive. The upgrading and expansion plans for Mahkota Medical Centre and Regency Specialist Hospital are on track to meet the increasing medical demand in the region.

  • Both hospitals will add c.30 operational beds each (or +15% YoY), leading to a total bed capacity of 500 by end-FY18.
  • Mahkota is also expanding its Radiology and other departments for more clinical areas and is expected to be completed by end-2018.
  • The construction of its new hospital extension block at Regency is expected to commence in FY18 after obtaining necessary approvals and is slated to commission in FY21.

The S$11.0mn net proceeds from the Placement Shares to Heliconia Capital Management is earmarked for the Group’s business expansion and has not yet been utilised.

Maintain BUY with unchanged DCF-derived TP of S$0.83

We maintain our view that HMI will benefit from the socioeconomic tailwinds arising from (i) public and private initiatives to improve infrastructure and regional connectivity; (ii) increasing domestic insurance take-up rate; (iii) favourable demographics; and (iv) cost competitive pricing compared to regional peers. 

The Group targets to reach 840 aggregate bed capacity – Mahkota (eventual capacity of 340 beds) and Regency (eventual capacity of 500 beds).

Important Information

This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.

By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.

The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.

Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.

This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.

Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.

Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.

Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.

To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.

The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.

This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.

This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.

IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSE

Where the report contains research analyses or reports from a foreign research house, please note:

  1. recipients of the analyses or reports are to contact Phillip Securities Research (and not the relevant foreign research house) in Singapore at 250 North Bridge Road, #06-00 Raffles City Tower, Singapore 179101, telephone number +65 6533 6001, in respect of any matters arising from, or in connection with, the analyses or reports; and
  2. to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, Phillip Securities Research accepts legal responsibility for the contents of the analyses or reports.
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments

About the author

Profile photo of Soh Lin Sin

Soh Lin Sin
Investment Analyst
Phillip Securities Research Pte Ltd

Lin Sin has been an investment analyst in Phillip Securities Research since June 2014, where she started as an economist, focusing on China and ASEAN macroeconomics. Currently, she covers primarily the Consumers and Healthcare sectors in Singapore equities market.

She graduated with a Bachelor of Science in Mathematics and Economics from NTU.

Get access to all the latest market news, reports, technical analysis
by signing up for a free account today!